Genetic prion disease: more detail

Definition and inheritance

Genetic prion disease is caused by a pathogenic variant in PRNP, the gene encoding prion protein. MedlinePlus Genetics puts the familial share of all prion disease at 10 to 15 percent, with 85 to 90 percent sporadic or acquired and 1 to 2 percent iatrogenic. CDC gives familial disease as 5 to 15 percent of CJD cases, so a range is the fair way to quote this.

Inheritance is autosomal dominant: one altered copy of PRNP is sufficient. A case can arise from an affected parent or from a de novo variant, and that second route is worth remembering when a family insists there is no history. Penetrance is variable and age-dependent, and families are often told the disease has skipped a generation when in fact a carrier died of something else first.

The recognised phenotypes are genetic CJD, Gerstmann-Straussler-Scheinker syndrome and fatal familial insomnia. CDC’s criteria for familial CJD are met by definite or probable CJD in the patient together with definite or probable CJD in a first-degree relative, or by a neuropsychiatric disorder with a disease-specific PrP gene mutation.

Variants and what they look like

The variants most often seen in surveillance series are E200K, V210I, V180I and D178N in genetic CJD, D178N in fatal familial insomnia, and P102L, P105S and A117V in Gerstmann-Straussler-Scheinker syndrome. D178N produces either genetic CJD or fatal familial insomnia depending on which codon 129 allele sits on the same chromosome, which is a useful illustration for families of why the same variant can mean different things.

E200K is the best characterised variant epidemiologically. The 2026 Israeli practice framework describes it as a founder variant that is relatively common among Libyan and Tunisian Jewish individuals and also found in Jews from other countries and in other ethnic groups, with likely hundreds to thousands of asymptomatic heterozygotes in Israel. In that population the authors describe penetrance as age-dependent, approaching complete by the ninth decade, with mean onset in the early 60s but wide variation. Those are population observations about one variant in one country, and they do not give a figure for any individual.

Clinically, genetic cases broadly follow the sporadic pattern with a slower course, often around two years, and Gerstmann-Straussler-Scheinker syndrome and fatal familial insomnia have their own distinct presentations. The symptom detail is on symptoms: more detail.

Diagnosis in a symptomatic person

The approach is the same as for sporadic disease: the clinical syndrome and its pace, cerebrospinal fluid RT-QuIC, MRI, EEG, with neuropathology for certainty, plus PRNP sequencing. The standard seeding assays detect some genetic subtypes less reliably than classic sporadic CJD, so a negative RT-QuIC in a person with a known family variant should not close the question. How it is diagnosed sets out the sequence.

Counselling well relatives

Genetic counselling comes before any test, and declining a test is a legitimate outcome of that process. Nobody should be steered in either direction.

The 2026 Israeli framework is the most detailed published description of how one national service does this, and its structure transfers even where local regulation differs. Its recommendations are that asymptomatic relatives of patients with genetic CJD should be offered genetic counselling, provided by genetic health professionals or neurologists familiar with the disease. Testing is not offered below the age of 18, and young adults need careful consideration. The panel did not proactively offer testing on the basis of Libyan or Tunisian ancestry alone, citing stigma and unnecessary distress. People in acute distress, such as shortly after a relative’s diagnosis or death, are encouraged to delay testing by at least six months.

The process runs in four structured steps, with at least a month between counselling and blood sampling. A pre-test psychological appraisal by a psychiatrist or clinical psychologist is used to evaluate readiness for a positive result, with written confirmation; the panel did not reach agreement on how to handle someone who declines that appraisal. Results, positive or negative, are delivered in person by the same trained clinician or genetic counsellor who did the initial counselling. Laboratory results go only to the referring team, not directly to patients, relatives or other providers, and the framework flags that a positive result can reveal the status of other family members. The panel also recommends that health systems develop a structured and easily accessible support programme for carriers, and that carriers be offered the opportunity to join research studies, which can themselves provide follow-up and contact.

European services describe similar structures. Hospital Clinic Barcelona runs PICOGEN, a programme of information and genetic counselling for familial dementias, which provides information to relatives of patients with genetic prion diseases about the possibility of inheriting the disease and its implications, offers them the option of finding out whether they are carriers of the gene, and covers preventing transmission of the causal mutation to their children. What is available, and who pays, differs by country, so the local genetics service is the authority on any individual pathway.

Reproductive options

These questions often arrive before anyone has decided about testing at all, and they can be discussed in the abstract without a test.

Preimplantation genetic testing has been used in this disease. Uflacker and colleagues reported in JAMA Neurology in 2014 what they describe as the first case of preimplantation genetic diagnosis with in vitro fertilisation used to prevent genetic prion disease, in an asymptomatic 27-year-old woman from a family with Gerstmann-Straussler-Scheinker syndrome due to PRNP F198S. Six embryos were free of the variant, two were transferred, and the resulting twins were developing normally at 27 months. The authors concluded that in vitro fertilisation with preimplantation genetic diagnosis is a viable option for couples who wish to avoid passing the disease on, and that neurologists should be aware of it so they can advise at-risk families. They also suggested its availability may affect decisions about predictive testing.

The Israeli framework’s fifth recommendation is that prenatal testing and preimplantation genetic testing for genetic CJD be considered on a case-by-case basis with individualised decision-making. It records that direct preimplantation genetic testing for a known variant is publicly funded in Israel for up to two healthy offspring, and that exclusion testing is available at tertiary centres to first- and second-degree relatives. It notes that prenatal diagnosis is possible by chorionic villus sampling from about 11 to 12 weeks and amniocentesis from about 17 to 23 weeks, and that ending a pregnancy after a positive result raises major ethical issues. A faster timeline may be needed in pregnancy, though the panel holds that all four steps should still take place.

Reproductive medicine and clinical genetics are the services that can discuss any of this for a particular couple.

Care and symptom management

Supportive care follows the same recommendations as the other prion diseases: early palliative involvement, treatment of myoclonus that causes distress with levetiracetam first line, neuropsychiatric symptoms approached as the communication of an unmet need, and structured support for carers. The longer course of many genetic cases makes advance care planning more feasible, and worth starting early. What to expect is the family-facing version.

Research

Genetic prion disease is where prion therapeutics are most likely to be tested first, because carriers can in principle be identified before symptoms begin.

The completed human trials, flupirtine, pentosan polysulphate, quinacrine and doxycycline, enrolled symptomatic patients, mostly with sporadic disease, and none established benefit in a controlled design. The stated lesson was that compounds effective only before symptoms in animals should be tested in people without symptoms, which in turn requires a predictive biomarker and a registry.

Preclinical work is aimed at lowering prion protein. A 2025 Nature Medicine report from the Broad Institute describes dual-AAV base editing installing a PRNP R37X change, with 37 percent average installation of the desired edit, 50 percent reduction of prion protein in mouse brain and 52 percent extension of lifespan in transgenic human PRNP mice inoculated with human prion isolates. A related epigenetic editor, CHARM, removed more than 80 percent of prion protein in mouse brain, against earlier work indicating that as little as 21 percent lowering can improve symptoms. All of this is mouse data, and the MIT account states that these tools have many hurdles to pass before anyone knows whether they work as therapeutics.

Studies open to recruitment, including any open to people without symptoms, are listed with sponsor-stated eligibility under current trials, and the research-facing account is on our research page. The plain version of this page is genetic prion disease.